RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...gv, thanks for the laugh but i think you again miss the point (which is a questioning again of RVX competence)...RVX did a huge turn for this now DM focused trial which calls into question a lot of the previous science knowledge at RVX (why now) so i asked the basic and important Q as to why isn't RVX doing a 208 mono arm which IMO is more relevant than adding a lipitor-208 arm so late and after RVX was out publicly pumping a supposed PIII trial design ... but the inclusion now of lipitor should raise questions as as best i know liptor-208 failed in assure and RVX IMO failed to do enough pre-trial work re. lipitor-208 to know it would likely fail and then they later claimed they now know why it failed...so they do diabetes now including lipitor-208 knowing full well the "ancillary" benefits of APo, etc won't be there (which if i read the science stuff is all kinda interrealted)
...and IMO RVX should still do a 208 mono arm, statins do have some bad side effects, i suspect a 208 mono arm (for diabetes and target pop) would have a good a chance of success as the combo's...but IMO it still speaks to the RVX wandering around the light pole looking for summin....ps the "market" is the high risk DM market, not some supposed maybed "off-label" market.. ps did RVX ever breakout lipitor 208 data in any of the P3 slide shows aside from ASSURE failure stuff...regards